Raffit Hassan

机构：National Institutes of Health, National Cancer Institute · ORCID：0000-0002-4012-3633

发表论文 373 篇 · 总被引 14986 次 · h-index 64

代表论文

• Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results (2023 · Nature Medicine · 被引 112)
• Treatment of Pleural Mesothelioma: ASCO Guideline Update (2025 · Journal of Clinical Oncology · 被引 59)
• Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope (2024 · Proceedings of the National Academy of Sciences · 被引 30)
• Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma (2024 · Lung Cancer · 被引 18)
• Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome (2024 · JAMA Dermatology · 被引 18)
• Robust differentiation of NK cells from MSLN.CAR-IL-15–engineered human iPSCs with enhanced antitumor efficacy against solid tumors (2025 · Science Advances · 被引 12)